10 Reasons Why CROs Leverage CluePoints For RBQM
Written by Andrea McSweeney, Vice President of Customer Success – Channel, CluePoints Contract research organizations (CROs) are uniquely positioned to partner with sponsors on risk
CluePoints To Share Case Study On Technology ROI At The SCDM 2022 EMEA Leadership Forum & Conference
Decentralized clinical trials (DCTs) have become a buzzphrase in recent years, with commentators lining up to extol the benefits of this new way of working.
Join Us At DIA 2022 As We Demystify The De-Risking Of DCTs
The world of decentralized clinical trials (DCTs) and risk-based quality management is evolving rapidly – but CluePoints and our partners are here to help you
10 Ways The Pandemic Changed CluePoints
AUTHOR: PATRICK HUGHES, CO-FOUNDER & CHIEF COMMERCIAL OFFICER, CLUEPOINTS As CluePoints celebrates ten years as the leading provider of Risk-Based Study Execution (RBx) and Risk-Based
Does Central Monitoring Lead To Higher Quality? An Analysis Of KRI Outcomes
AUTHOR: SYLVIANE DE VIRON, MANAGER, DATA & KNOWLEDGE, CLUEPOINTS AND WILLIAM STEIJN, RESEARCH DATA ANALYST, CLUEPOINTS Central Monitoring is a key component of Risk-Based Quality
10 Ways Mid-Sized BioPharma Has Applied A Pragmatic Approach To RBQM Implementation
AUTHOR: DAN BEAUDRY, SENIOR VICE PRESIDENT, CUSTOMER SUCCESS As the shift towards decentralized clinical trials accelerates, powered by the COVID-19 pandemic as well as the
FDA Places Quality Management At The Heart Of Updated Inspection Guide
AUTHOR: PATRICK HUGHES, CO-FOUNDER & CHIEF COMMERCIAL OFFICER, CLUEPOINTS It’s official: Risk-Based Quality Management (RBQM) is essential for the smooth running of clinical trials. The
CluePoints Co-Founder And Chief Executive Officer To Speak At SCOPE Europe
Francois Torche, Co-Founder and Chief Executive Officer at CluePoints, will share insights into utilizing Risk-Based Quality Management (RBQM) to improve trial outcomes at this year’s
臨床試験の分散化：障壁緩和と導入への推進
著者: JOHN HALL, SVP, BUSINESS DEVELOPMENT, EMEA & APAC CluePoints 社 EMEA & APA SVP 担当である John Hall が、 分散型臨床試験の成長を促進する市場要因と、 この機会を完全に捉えるために取り除く必要のある障害について詳しく説明いたします。 分散型臨床試験導入への加速化 現在、分散型臨床試験(DCT)はCOVID-19も引き続き大変興味深いトレンドとなっています。 COVID-19の大流行により、バーチャルまたは分散型臨床試験は、臨床試験実施において、現在より患者中心のアプローチをとり、プロセスに利便性と柔軟性をもたらし、参加者が日々快適な環境から試験に参加できることが可能となっています。
Decentralized Clinical Trials: Alleviating Barriers And Driving Adoption
AUTHOR: JOHN HALL, SVP, BUSINESS DEVELOPMENT, EMEA & APAC John Hall, SVP, EMEA & APAC at CluePoints, discusses the market factors driving Decentralized Clinical Trial
